![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 7, 2024
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 9, 2024
The co-chairs commemorate the late Dr. Edith Mitchell, welcome the new NCI Director, and reflect on the DREAMseq melanoma trial results
February 9, 2024
In January, the medical community lost an acclaimed oncology physician, researcher, teacher, and health equity pioneer
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
February 9, 2024
A member of ECOG-ACRIN since 2014
February 9, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more